1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease

T Coleman, SW Ellis, IJ Martin, MS Lennard and GT Tucker

University of Sheffield, Department of Medicine & Pharmacology, Royal Hallamshire Hospital, UK.

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induces a Parkinson- like syndrome through biotransformation by monoamine oxidase B to the neurotoxic metabolite 1-methyl-4-phenylpyridine. Neuroprotection may be provided by parallel N-demethylation and N-oxidation pathways mediated by the microsomal cytochrome P450 and flavin monooxygenase systems, respectively. The aims of this study were to characterise the N- demethylation of MPTP by human liver microsomes over a wide range of concentrations, and to identify the cytochrome P450 enzymes involved in this reaction. The kinetics of the N-demethylation of MPTP (1 microM - 3 mM) by microsomes from the liver of an extensive metabolizer with respect to cytochrome P4502D6 (CYP2D6) activity were biphasic (apparent Km1 and Km2 values = 48 and 2882 microM). The high affinity activity was abolished in the presence of quinidine (1 microM) and was absent in microsomes from a genotypically poor metabolizer with respect to CYP2D6. Yeast microsomes containing heterologously expressed CYP2D6 N- demethylated MPTP (Km = 39 microM), and there was a high correlation between the quinidine-inhibitable N-demethylation of MPTP (50 microM) (0.7-91%, mean 44%, of total activity) and the alpha-hydroxylation of metoprolol in microsomes from 11 human livers (rs = 0.92; P < .001). At 50 microM MPTP, N-demethylase activity in human liver microsomes was also inhibited by furafylline (10 microM) and ketoconazole (2 microM) (mean inhibition 39 and 13%, respectively; n = 11 livers). Yeast microsomes containing heterologously expressed human CYP1A2 N- demethylated MPTP with a Km of 2246 microM. These findings indicate that CYP2D6, CYP1A2 and, to a lesser extent CYP3A4, may have a role in protecting against Parkinson's disease induced by MPTP and other potential environmental neurotoxins. The data provide some biochemical support for the proposition that genotypically poor metabolizers with respect to CYP2D6 are overrepresented in some populations of Parkinson's patients, and that smokers (induced CYP1A2?) are underrepresented.

Volume 277, Issue 2, pp. 685-690, 05/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				A. S. Kalgutkar, S. Zhou, O. A. Fahmi, and T. J. Taylor Influence of Lipophilicity on the Interactions of N-Alkyl-4-phenyl-1,2,3,6-tetrahydropyridines and Their Positively Charged N-Alkyl-4-phenylpyridinium Metabolites with Cytochrome P450 2D6 Drug Metab. Dispos., May 1, 2003; 31(5): 596 - 605. [Abstract] [Full Text] [PDF]

				C. M. Thompson, J. H. Capdevila, and H. W. Strobel Recombinant Cytochrome P450 2D18 Metabolism of Dopamine and Arachidonic Acid J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 1120 - 1130. [Abstract] [Full Text]

				S.'i. Yoshihara, K. Harada, and S. Ohta Metabolism of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Perfused Rat Liver: Involvement of Hepatic Aldehyde Oxidase as a Detoxification Enzyme Drug Metab. Dispos., May 1, 2000; 28(5): 538 - 543. [Abstract] [Full Text]

				P. J. Kramer, J. Caldwell, A. Hofmann, P. Tempel, and G. Weisse Neurotoxicity risk assessment of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) as a synthetic impurity of drugs Human and Experimental Toxicology, May 1, 1998; 17(5): 283 - 293. [Abstract] [PDF]